Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Biotech's big-bucks buybacks begin to burn
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Clearside’s future clouds over
After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.
Roche goes for death or glory with faricimab
Roche is stepping up the defence of its eye franchise, but the real test will come with pivotal readouts for its new contender versus Regeneron’s Eylea.
The most disputed sales outlooks in biopharma
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
Pegging US Medicare prices to international index not the easy answer it looks
The price isn’t the real price, even in overseas markets. And if the US government is serious about drug price reductions, should it return to the idea of direct…
Amgen drops Repatha's list price as US elections loom
Repatha's price reduction could say more about the state of US politics and competition than it does about long term cost-lowering.
New tanezumab pain for Pfizer and Lilly
Pfizer and Lilly appear to have sacrificed some efficacy for safety with their anti-NGF pain project, tanezumab.
Esmo 2018 – Without overwhelming efficacy the me-too PD-1 chase is futile
Results from Tesaro, Sanofi, Novartis, Merck KGaA and others have come in thick and fast, but can any beat the entrenched leaders?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.